CN112386593B - 一种含西达本胺的抗肿瘤药物组合物及其应用 - Google Patents
一种含西达本胺的抗肿瘤药物组合物及其应用 Download PDFInfo
- Publication number
- CN112386593B CN112386593B CN202010812248.3A CN202010812248A CN112386593B CN 112386593 B CN112386593 B CN 112386593B CN 202010812248 A CN202010812248 A CN 202010812248A CN 112386593 B CN112386593 B CN 112386593B
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- alk
- met
- cancer
- ros1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 title claims abstract description 14
- 229960004034 sitagliptin Drugs 0.000 title claims abstract description 14
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 11
- 239000003112 inhibitor Substances 0.000 claims abstract description 50
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims abstract description 37
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims abstract description 29
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract 8
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 4
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract 4
- 230000007704 transition Effects 0.000 claims abstract 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical group O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 42
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 41
- 229960005061 crizotinib Drugs 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 230000005764 inhibitory process Effects 0.000 claims description 12
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 claims description 5
- 229950004272 brigatinib Drugs 0.000 claims description 5
- 229960001602 ceritinib Drugs 0.000 claims description 5
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical group CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 4
- 229960002798 cetrimide Drugs 0.000 claims description 4
- 229950000521 entrectinib Drugs 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 229950001290 lorlatinib Drugs 0.000 claims description 4
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 claims description 4
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 claims description 4
- FIKPXCOQUIZNHB-WDEREUQCSA-N repotrectinib Chemical compound C[C@H]1CNC(=O)C2=C3N=C(N[C@H](C)C4=C(O1)C=CC(F)=C4)C=CN3N=C2 FIKPXCOQUIZNHB-WDEREUQCSA-N 0.000 claims description 4
- 229940121602 repotrectinib Drugs 0.000 claims description 4
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims description 3
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 229960001292 cabozantinib Drugs 0.000 claims description 3
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 229950005976 tivantinib Drugs 0.000 claims description 3
- RYBLECYFLJXEJX-UHFFFAOYSA-N CN1C=C(C=N1)C1=CN2C(C=C1)=NC=C2S(=O)(=O)N1N=CC2=NC=C(C=C12)C1=CN(C)N=C1 Chemical compound CN1C=C(C=N1)C1=CN2C(C=C1)=NC=C2S(=O)(=O)N1N=CC2=NC=C(C=C12)C1=CN(C)N=C1 RYBLECYFLJXEJX-UHFFFAOYSA-N 0.000 claims description 2
- 230000004544 DNA amplification Effects 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 229960001611 alectinib Drugs 0.000 claims description 2
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 201000002523 pancreas lymphoma Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000008707 rearrangement Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 3
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000003208 gene overexpression Methods 0.000 claims 1
- 230000030279 gene silencing Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 37
- 238000011580 nude mouse model Methods 0.000 description 17
- 241000699660 Mus musculus Species 0.000 description 14
- 239000000725 suspension Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 102000003964 Histone deacetylase Human genes 0.000 description 5
- 108090000353 Histone deacetylase Proteins 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001973 epigenetic effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000029578 entry into host Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 description 1
- -1 2-amino-4-fluorophenyl Chemical group 0.000 description 1
- LVZIYCVMFGATIW-GFCCVEGCSA-N 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-pyridin-4-ylpyrazol-4-yl)pyridin-2-amine Chemical compound ClC1=C(C(=CC=C1F)Cl)[C@@H](C)OC=1C(=NC=C(C1)C=1C=NN(C1)C1=CC=NC=C1)N LVZIYCVMFGATIW-GFCCVEGCSA-N 0.000 description 1
- QQWUGDVOUVUTOY-UHFFFAOYSA-N 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)C(C)C QQWUGDVOUVUTOY-UHFFFAOYSA-N 0.000 description 1
- 101150023956 ALK gene Proteins 0.000 description 1
- GCYIGMXOIWJGBU-UHFFFAOYSA-N AZD3463 Chemical compound C=1C=C(NC=2N=C(C(Cl)=CN=2)C=2C3=CC=CC=C3NC=2)C(OC)=CC=1N1CCC(N)CC1 GCYIGMXOIWJGBU-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
- 101000836339 Homo sapiens Transposon Hsmar1 transposase Proteins 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 241001676573 Minium Species 0.000 description 1
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000004422 Phospholipase C gamma Human genes 0.000 description 1
- 108010056751 Phospholipase C gamma Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101150035397 Ros1 gene Proteins 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 102100027172 Transposon Hsmar1 transposase Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229950008692 foretinib Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
- 229910052611 pyroxene Inorganic materials 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及医药领域,具体涉及一种含西达本胺的抗肿瘤药物组合物及其应用。本发明提供了一种含西达本胺的抗肿瘤药物组合物,它含有西达本胺和细胞间质上皮转换因子(cellular‑mesenchymal epithelial transition factor,c‑Met)抑制剂,或者含有西达本胺和间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)抑制剂,或者含有西达本胺和repressor of silencing 1(ROS1)抑制剂。
Description
本申请要求于2019年08月15日提交中国专利局、申请号为201910754966.7、发明名称为“一种含西达本胺的抗肿瘤药物组合物及其应用”的中国专利申请的优先权,其全部内容通过引用结合在本申请中。
技术领域
本发明涉及医药领域,具体涉及一种含西达本胺的抗肿瘤药物组合物及其应用。
背景技术
西达本胺具有下式(1)结构,其化学名称为N-(2-氨基-4-氟苯基)-4-[N-[(E)-3-(3-吡啶)丙烯酰基]氨甲基]苯甲酰胺。
西达本胺是深圳微芯生物科技股份有限公司独家发现的新分子实体药物,机制新颖,是全球首个亚型选择性组蛋白去乙酰化酶(HDAC)抑制剂和全球首个获批治疗外周T细胞淋巴瘤的口服药物,属于表观遗传调控剂类药物。
西达本胺具有对肿瘤发生发展相关的表观遗传异常的重新调控作用,作用于表观遗传相关靶点-组蛋白去乙酰化酶(第I类的1、2、3亚型和第IIb类的10亚型)。组蛋白去乙酰化酶(HDAC)是一类对染色体的结构修饰和基因表达调控发挥重要作用的蛋白酶,西达本胺作为HDAC抑制剂,通过抑制HDAC的生物学活性产生作用,并由此产生针对肿瘤发生的多条信号传递通路基因表达的改变(即表观遗传改变)。
ALK(间变性淋巴瘤激酶,anaplastic lymphoma kinase)基因是一种跨膜受体酪氨酸激酶,可在多种恶性肿瘤中发生变异或与其他癌基因融合,是肿瘤的致癌驱动基因。ALK可激活多个细胞内信号通路,包括磷脂酶Cγ,JAK激酶、信号转导和转录激活因子(signaltransducer and activator of transcription-3,STAT3)、磷脂酰肌醇-3-激酶(phosphatidylinositol 3-kinase,PI3K)、哺乳动物雷帕霉素靶蛋白(mammaliantargetof rapamycin,mTOR)及丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)等,参与调节细胞生长、转化及抗细胞凋亡。在多种肿瘤中均发现了ALK基因重组、突变或扩增,包括淋巴瘤、神经母细胞瘤及非小细胞肺癌。近年来靶向ALK融合基因已成为NSCLC治疗的前沿手段,第一、二、三代ALK酪氨酸激酶抑制剂治疗ALK阳性的NSCLC显示出较好的疗效,但仅在一定时间内对特定人群有效。ALK抑制剂包括克唑替尼(crizotinib)、色瑞替尼(ceritinib)及艾乐替尼(alectinib)等。
细胞间质上皮转换因子(cellular-mesenchymal epithelial transitionfactor,c-Met),又被称为肝细胞生长因子受体(Hepatocyte growth factor receptor,HGFR),是受体酪氨酸激酶家族中一类独特的亚族。c-Met信号通路对胚胎发育和产后器官再生期间的侵袭性生长具有关键作用。通常成人只有在伤口愈合和组织再生的过程中c-Met信号通路才被完全激活,但肿瘤c-Met信号通路能被癌细胞频繁激活,促使肿瘤形成、侵袭性生长和转移。据报道,c-Met信号通路在多种类型的实体瘤(肺癌、胃癌、肝癌、乳腺癌、皮肤癌、大肠癌等)中均存在异常调节的现象,并且在结直肠癌肝转移,口腔鳞癌的形成、生长、转移,乳腺癌、卵巢癌和胃癌的侵袭、转移,以及肝癌、肺癌和胰腺癌等的发生发展中发挥重要的作用。由于异常的c-Met信号在人类肿瘤形成、侵袭和转移中的重要作用。因此,抑制c-Met信号成为癌症治疗的重要策略。c-Met抑制剂包括厄洛替尼、吉非替尼(gefitinib)、卡博替尼、戈伐替尼、福瑞替尼、替伐替尼、克唑替尼和卡扎替尼等。
ROS1(c-ros原癌基因1,c-ros oncogene 1)融合基因是RIKOVA等于2007年首次在肺腺癌患者组织中分离出的靶基因,发生率约占NSCLC的1.0%~3.4%。尽管罕见,ROS1作为新的肺癌驱动基因,被证实为有潜力的NSCLC治疗新靶点。ROS1酪氨酸激酶作为一个关键的跨膜受体蛋白酪氨酸激酶,控制细胞凋亡、生存、分化及增殖等多个细胞进程,对多种恶性肿瘤的治疗有重要作用。近年来,一些靶向ROS1小分子抑制剂被相继报道,ROS1抑制剂包括克唑替尼、色瑞替尼、brigatinib、AZD-3463、NVP-TAE684、foretinib和cabozantinib等,2-氨基嘧啶类、4-芳氨基喹啉类等化合物相继被报道具有较强的ROS1激酶抑制活性,此外,一些选择性ROS1抑制剂也被开发出来。
克唑替尼(crizotinib)具有下式(2)结构,其化学名称是:3-[(R)-1-(2,6-二氯-3-氟苯基)乙氧基]-5-[1-(吡啶-4-基)-1H-吡唑-4-基]吡啶-2-胺。
克唑替尼是由辉瑞公司研制的抑制Met/ALK/ROS的ATP竞争性的多靶点蛋白激酶抑制剂。分别在ALK、ROS和MET激酶活性异常的肿瘤患者中证实克唑替尼对人体有显著临床疗效。克唑替尼2011年被美国FDA批准用于治疗间变性淋巴瘤激酶(ALK)阳性的NSCLC晚期患者的小分子靶向药物,已在临床应用于ALK阳性非小细胞肺癌的治疗。克唑替尼靶向作用于ALK蛋白,抑制其酪氨酸激酶域的磷酸化,使其不能活化,从而调控下游信号蛋白PI3K、AKT和mTOR的活化形式p-PI3K、p-AKT和p-mTOR的表达。
目前,未见有将西达本胺与c-Met抑制剂、间变性淋巴瘤激酶(anaplasticlymphoma kinase,ALK)抑制剂或repressor of silencing 1(ROS1)抑制剂联合应用已用于肿瘤治疗的研究。
发明内容
本发明人在研究中意外发现:将西达本胺与c-Met/ALK/ROS1抑制剂联用,可实现协同抗肿瘤作用。
因此,本发明提供了一种含西达本胺的抗肿瘤药物组合物,它含有西达本胺和c-Met抑制剂,或者含有西达本胺和间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)抑制剂,或者含有西达本胺和repressor of silencing 1(ROS1)抑制剂。
所述c-Met抑制剂包括而不限于crizotinib、cabozantinib、tivantinib、glumetinib等具有c-Met抑制活性的药物。
所述ALK抑制剂包括而不限于ceritinib、alectinib、crizotinib、brigatinib、repotrectinib、entrectinib、lorlatinib等具有ALK抑制活性的药物。
所述ROS1抑制剂包括而不限于crizotinib、brigatinib、repotrectinib、entrectinib、lorlatinib等具有ROS1抑制活性的药物。
所述西达本胺和c-Met抑制剂的重量比为1:1~1:5。
所述西达本胺和ALK抑制剂的重量比为1:1~1:5。
所述西达本胺和ROS1抑制剂的重量比为1:1~1:5。
本发明的上述药物组合物还可包含药学上可接受的载体。
同时,本发明还提供了上述药物组合物在制备治疗c-Met或ALK或ROS1发生基因扩增、重排、过表达或其他形式突变等的恶性肿瘤的药物中的用途。
所述恶性肿瘤包括而不限于肺癌、胃癌、肝癌、乳腺癌、皮肤癌、肠癌、卵巢癌、胰腺癌、淋巴瘤、神经母细胞瘤。
进一步的,本发明提供了一种药盒,它含有上述药物组合物。
本发明的药盒中,所述西达本胺与c-Met抑制剂、ALK抑制剂或ROS1抑制剂分别是具有相同或不同规格的单位制剂。所述西达本胺与c-Met抑制剂、ALK抑制剂或ROS1抑制剂分别置于单独容器中提供。所述西达本胺分别与c-Met抑制剂、ALK抑制剂或ROS1抑制剂的重量比为1:1~1:5。
最后,本发明提供了一种治疗恶性肿瘤的方法,其包括向有需要的患者施用治疗有效量的上述药物组合物或药盒的步骤。其中,所述西达本胺与c-Met抑制剂、ALK抑制剂或ROS1抑制剂同时、分别或依次给药。
本发明经MTS实验发现,组蛋白去乙酰化酶抑制剂西达本胺和c-Met/ALK/ROS1抑制剂克唑替尼的联合给药能够在肺癌细胞系Calu-3、HCC827、NCI-H460,胃癌细胞系AGS和淋巴瘤细胞系KARPAS-299中产生协同抑制效果,即两药联合时对肿瘤细胞的抑制作用强于两药单独应用所产生抑制作用之和。同时在HCC827和KARPAS-299裸鼠移植瘤模型上验证了西达本胺和克唑替尼联用的协同抗肿瘤药效。
附图说明
图1:在肺癌细胞系中西达本胺协同增敏c-Met/ALK/ROS1抑制剂(克唑替尼);
图2:在胃癌、淋巴瘤细胞系中西达本胺协同增敏c-Met/ALK/ROS1抑制剂(克唑替尼);
图3:在裸鼠动物试验中西达本胺与c-Met/ALK/ROS1抑制剂(克唑替尼)联合给药的协同抗肿瘤药效。
具体实施方式
本发明公开了西达本胺和c-Met/ALK/ROS1抑制剂的组合及其在治疗癌症中的用途,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明所述应用和药用组合物已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述应用和药用组合物进行改动或适当变更与组合,来实现和应用本发明技术。
实验部分
实验材料:
人肺癌细胞系Calu-3、HCC827、NCI-H460,人胃癌细胞系AGS和人淋巴瘤细胞系KARPAS-299均购自美国典型培养物保藏中心(american type culture collection,ATCC),于37℃,5%CO2条件下常规培养,其中,HCC827、NCI-H460和KARPAS-299的培养液为含10%胎牛血清(Fetal bovine serum,FBS;Gibco)和1%Penicillin-Streptomycin(HyClone)的RPMI-1640(Gibco),Calu-3的培养液为含10%FBS和1%Penicillin-Streptomycin的minimum Eagle’s medium(MEM,Gibco),AGS的培养液为含10%FBS和1%Penicillin-Streptomycin的F12(Gibco)。胰蛋白酶(Trypsin)购自于Gibco;MTS细胞活性检测试剂盒购自于Promega。裸鼠购自于广东省医学实验动物中心。
实施例1.MTS实验
实验方法:
将贴壁培养细胞系Calu-3、HCC827、NCI-H460、AGS通过Trypsin消化收集并计数,悬浮培养细胞系KARPAS-299吸打混匀并计数后,按每孔3000个/180μL接种于96孔细胞培养板中,5%CO2、37℃培养。细胞接种过夜后按图1及图2所示的分组和终浓度剂量给药(给药后每孔最终体积均为200μL),每个分组剂量设置3个复孔。药物处理144小时后,每孔加入20μL MTS细胞活性检测试剂,其中MTS和PMS体积比为20:1,在未种细胞的孔中加入同样体积的培养液和MTS细胞活性检测试剂作为检测背景(OD490-BLK)。37℃孵育约1小时后,通过酶标仪读取每孔490nm波长处的吸光度值。各孔读数减去OD490-BLK后获得扣除检测背景的各给药孔OD490-T及阴性对照孔OD490-T0。
各给药孔细胞的相对存活率按以下公式计算:
细胞相对生长率=OD490-T/OD490-T0×100%
实验结果:
如图1a所示,人肺癌细胞系Calu-3、HCC827和NCI-H460中,西达本胺单药均显现出一定的抑制肿瘤细胞增殖作用,且呈剂量依赖性,通过Graphpad软件测算,西达本胺单药对上述三株细胞系的50%抑制剂量GI50(西达本胺单药)分别为7.612μM、4.416μM和7.492μM。图1b中显示了克唑替尼单药及0.5μM西达本胺联合梯度剂量克唑替尼对上述三株细胞系产生的剂量依赖性增殖抑制作用,克唑替尼单药对三株肺癌细胞系的GI50(克唑替尼单药)分别为2.546μM、1.052μM和1.668μM,而克唑替尼与0.5μM西达本胺联合使用时对三株细胞系的GI50(克唑替尼联合)分别为1.117μM、0.336μM和1.114μM,此时视GI50(西达本胺联合)为0.5μM。
如图2所示,人胃癌细胞系AGS中,GI50(西达本胺单药)为2.465μM、GI50(克唑替尼单药)为0.405μM、GI50(克唑替尼联合)分别为0.140μM、视GI50(西达本胺联合)为0.5μM。而人淋巴瘤细胞系KARPAS-299中,GI50(西达本胺单药)为0.019μM、GI50(克唑替尼单药)为0.022μM、GI50(克唑替尼联合)分别为0.004μM、视GI50(西达本胺联合)为0.01μM。
根据如下公式计算两种药物在各细胞系中联合使用时的协同指数(combinedindex,CI):
CI=GI50(西达本胺联合)/GI50(西达本胺单药)+GI50(克唑替尼联合)/GI50(克唑替尼单药)
一般认为,CI=1时,两药联用为叠加效应;CI>1时为拮抗效应;CI<1为协同效应,CI值越小表明协同效应越强。
如表1所示,在Calu-3、HCC827、NCI-H460、AGS和KARPAS-299中,西达本胺与克唑替尼联合用药时的协同度CI分别为0.504、0.432、0.734、0.548和0.706,表明两药在5株细胞系中均表现出较强的协同效应。
表1 50%抑制剂量(GI50)及协同指数(CI)
实施例2.裸鼠移植瘤模型实验
实验方法:
大量扩增培养HCC827细胞并使细胞保持在对数生长状态。待细胞数量达到所需后,胰酶消化收集,大量PBS充分清洗2次以去除胰酶和血清成分,室温、800rpm离心10min,弃上清。用不含FBS的RPIM-1640培养液重悬细胞,调整细胞浓度至107/300μL。
对悬浮培养的KARPAS-299细胞,同样大量扩增培养并使细胞保持在对数生长状态。待细胞数量达到所需后,离心收集细胞沉淀,大量PBS充分清洗2次以去除血清成分,室温、800rpm离心10min,弃上清。用不含FBS的RPIM-1640培养液重悬细胞,调整细胞浓度至107/300μL。
在无菌条件下,按300μL/针将细胞悬液注射至裸鼠背部皮下,每只裸鼠注射一针。注射时使用1mL一次性医用注射器,保证每只裸鼠进针部位和方向基本一致。
接种细胞后,每2天观察和测量接种部位是否成瘤,用游标卡尺测量接种部位可能出现肿块的最长径(length)及与之垂直的最宽径(width),通过公式TS=length×(width)2/2计算肿瘤体积并记录,以TS达到100立方毫米作为判断成瘤的标准。
观察到成瘤后,将成瘤裸鼠随机分成四组(即溶剂对照组、西达本胺组、克唑替尼组和联合用药组),标记并分笼饲养,每天按分组给药并观察肿瘤生长情况。每只裸鼠给药前测量体重,按每千克体重计算给药剂量,HCC827裸鼠中,溶剂对照组按每克体重10μL的CMC-Na溶液、西达本胺10毫克/公斤体重组按每克体重10μL的1mg/mL西达本胺-CMC-Na悬浊液、克唑替尼25毫克/公斤体重组按每克体重10μL的2.5mg/mL克唑替尼-CMC-Na悬浊液、联合用药组按每克体重10μL的每毫升含2.5mg克唑替尼和1mg西达本胺的CMC-Na悬浊液进行灌胃给药;KARPAS-299裸鼠中,溶剂对照组按每克体重10μL的CMC-Na溶液、西达本胺2毫克/公斤体重组按每克体重10μL的0.2mg/mL西达本胺-CMC-Na悬浊液、克唑替尼2.5毫克/公斤体重组按每克体重10μL的0.25mg/mL克唑替尼-CMC-Na悬浊液、联合用药组按每克体重10μL的每毫升含0.25mg克唑替尼和0.2mg西达本胺的CMC-Na悬浊液进行灌胃给药。每3~4天用游标卡尺测量、计算肿瘤体积并记录。每只裸鼠每天定时灌胃给药1次,当测量到有实验个体的肿瘤体积达到或超过2000立方毫米时,结束实验。
实验结果:
如图3a所示,在裸鼠HCC827移植瘤模型中,与溶剂对照组相比,西达本胺10毫克/公斤体重和克唑替尼25毫克/公斤体重两单独给药组在最终对裸鼠荷瘤体积均有一定抑制,而联合用药组的最终抑瘤率高于两单药组抑瘤率之和,表明两药在HCC827荷瘤裸鼠体内具有协同增敏抗肿瘤的活性。
如图3b所示,在裸鼠KARPAS-299移植瘤模型中,与溶剂对照组相比,西达本胺2毫克/公斤体重和克唑替尼2.5毫克/公斤体重两单独给药组在最终对裸鼠荷瘤体积均有明显的抑制,而联合用药组的最终抑瘤率则更为显著,高于两单药组抑瘤率之和,表明两药在KARPAS-299荷瘤裸鼠体内具有协同增敏抗肿瘤的活性。
以上对本发明提供的包含西达本胺和c-Met/ALK/ROS1抑制剂克唑替尼的组合及其应用进行了详细的介绍,本文中应用了具体实施例对本发明的原理及实施方式进行了阐述,以上实施例的说明只是用于帮助理解本发明的方法及其核心思想,包括最佳方式,并且也使得本领域的任何技术人员都能够实践本发明,包括制造和使用任何装置或系统,和实施任何结合的方法。应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以对本发明进行若干改进和修饰,这些改进和修饰也落入本发明权利要求的保护范围内。本发明专利保护的范围通过权利要求来限定,并可包括本领域技术人员能够想到的其他实施例。如果这些其他实施例具有不是不同于权利要求文字表述的结构要素,或者如果它们包括与权利要求的文字表述无实质差异的等同结构要素,那么这些其他实施例也应包含在权利要求的范围内。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (14)
1.一种含西达本胺的抗肿瘤药物组合物,其特征在于:它的活性成分由西达本胺和细胞间质上皮转换因子(cellular-mesenchymal epithelial transition factor,c-Met)抑制剂组成;所述c-Met抑制剂选自crizotinib、cabozantinib、tivantinib、glumetinib具有c-Met抑制活性的药物。
2.一种含西达本胺的抗肿瘤药物组合物,其特征在于:它的活性成分由西达本胺和间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)抑制剂组成;所述ALK抑制剂选自ceritinib、alectinib、crizotinib、brigatinib、repotrectinib、entrectinib、lorlatinib具有ALK抑制活性的药物。
3.一种含西达本胺的抗肿瘤药物组合物,其特征在于:它的活性成分由西达本胺和repressor ofsilencing 1(ROS1)抑制剂组成;所述ROS1抑制剂选自crizotinib、brigatinib、repotrectinib、entrectinib、lorlatinib具有ROS1抑制活性的药物。
4.根据权利要求1所述的药物组合物,其特征在于:所述西达本胺和c-Met抑制剂的重量比为1:1~1:5。
5.根据权利要求2所述的药物组合物,其特征在于:所述西达本胺和ALK抑制剂的重量比为1:1~1:5。
6.根据权利要求3所述的药物组合物,其特征在于:所述西达本胺和ROS1抑制剂的重量比为1:1~1:5。
7.根据权利要求1~6任一项所述的药物组合物,其特征在于:还包含药学上可接受的载体。
8.权利要求1~7任一项所述的药物组合物在制备治疗c-Met或ALK或ROS发生基因扩增、基因重排、基因过表达或其他基因突变的恶性肿瘤的药物中的用途。
9.根据权利要求8所述的用途,其特征在于:所述恶性肿瘤包括肺癌、胃癌、肝癌、乳腺癌、皮肤癌、肠癌、卵巢癌、胰腺癌、淋巴瘤、神经母细胞瘤。
10.一种药盒,其特征在于:它含有权利要求1~7任一项所述的药物组合物。
11.根据权利要求10所述的药盒,其特征在于:所述西达本胺与c-Met抑制剂、ALK抑制剂或ROS1抑制剂分别是具有相同或不同规格的单位制剂。
12.根据权利要求10~11任一项所述的药盒,其特征在于:所述西达本胺与c-Met抑制剂、ALK抑制剂或ROS1抑制剂分别置于单独容器中提供。
13.根据权利要求10~11任一项所述的药盒,其特征在于:所述西达本胺分别与c-Met抑制剂、ALK抑制剂或ROS1抑制剂的重量比为1:1~1:5。
14.根据权利要求12所述的药盒,其特征在于:所述西达本胺分别与c-Met抑制剂、ALK抑制剂或ROS1抑制剂的重量比为1:1~1:5。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910754966 | 2019-08-15 | ||
CN2019107549667 | 2019-08-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112386593A CN112386593A (zh) | 2021-02-23 |
CN112386593B true CN112386593B (zh) | 2023-11-21 |
Family
ID=74569402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010812248.3A Active CN112386593B (zh) | 2019-08-15 | 2020-08-13 | 一种含西达本胺的抗肿瘤药物组合物及其应用 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN112386593B (zh) |
TW (1) | TWI741731B (zh) |
WO (1) | WO2021027912A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023193705A1 (zh) * | 2022-04-07 | 2023-10-12 | 深圳微芯生物科技股份有限公司 | 西奥罗尼在抗胰腺癌中的用途 |
CN115322171B (zh) * | 2022-08-30 | 2023-03-17 | 深圳微芯生物科技股份有限公司 | 一种trka(g667c)和flt3靶点抑制剂及其与西达本胺的组合物 |
CN117427072B (zh) * | 2023-12-08 | 2024-05-31 | 苏州大学附属第二医院 | 西达本胺在制备用于治疗肾脏纤维化的药物中的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101837129A (zh) * | 2009-03-19 | 2010-09-22 | 鼎泓国际投资(香港)有限公司 | 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用 |
KR20180120565A (ko) * | 2018-01-25 | 2018-11-06 | 연세대학교 산학협력단 | Alk 저해제에 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 약물 선택의 정보 제공 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101653608B (zh) * | 2008-08-19 | 2013-02-13 | 鼎泓国际投资(香港)有限公司 | 含有肝细胞生长因子受体抑制剂和组蛋白去乙酰化酶抑制剂的药物组合物及其应用 |
TR201900059A2 (tr) * | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
CN110833544B (zh) * | 2018-08-17 | 2022-08-09 | 深圳微芯生物科技股份有限公司 | 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途 |
-
2020
- 2020-08-12 TW TW109127412A patent/TWI741731B/zh active
- 2020-08-13 CN CN202010812248.3A patent/CN112386593B/zh active Active
- 2020-08-14 WO PCT/CN2020/109102 patent/WO2021027912A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101837129A (zh) * | 2009-03-19 | 2010-09-22 | 鼎泓国际投资(香港)有限公司 | 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用 |
KR20180120565A (ko) * | 2018-01-25 | 2018-11-06 | 연세대학교 산학협력단 | Alk 저해제에 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 약물 선택의 정보 제공 방법 |
Non-Patent Citations (1)
Title |
---|
ZHANG,N.N.et al.."Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC".《Journal of Cancer》.2019,第10卷(第5期),第1275-1287页. * |
Also Published As
Publication number | Publication date |
---|---|
WO2021027912A1 (zh) | 2021-02-18 |
TW202114666A (zh) | 2021-04-16 |
CN112386593A (zh) | 2021-02-23 |
TWI741731B (zh) | 2021-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112386593B (zh) | 一种含西达本胺的抗肿瘤药物组合物及其应用 | |
CN105849110B (zh) | 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法 | |
EP2127652B1 (en) | Method for treating cancer using anticancer agent in combination | |
JP5758003B2 (ja) | 抗癌剤併用療法 | |
CN108295063A (zh) | 治疗增殖性疾病的联合疗法(威罗菲尼和mdm2抑制剂) | |
EP2605766A2 (en) | Novel combination therapy for the treatment of cancer | |
Wang et al. | Current development of glioblastoma therapeutic agents | |
CN111558044B (zh) | 一种包含舒尼替尼的药物组合物及其制剂和应用 | |
CN110522753A (zh) | 一种新型抗肿瘤药物组合物、制剂和应用 | |
CN103263416A (zh) | 一种吡啶胺化合物在制备适于口服给药的治疗肺癌的药物中的应用 | |
CN110664818B (zh) | 一种治疗肺癌的药物 | |
KR20220109389A (ko) | 릴피비린을 포함하는 조성물 및 종양 또는 암 치료를 위한 이의 용도 | |
CN101861159A (zh) | 改进的抗肿瘤治疗 | |
CN111617081B (zh) | 一种取代丁烯酰胺联合mTOR抑制剂的药物组合物及其用途 | |
CN112933239A (zh) | 激活肿瘤细胞内源性pd-1的试剂在制备抗肿瘤药物中的用途 | |
CN108653293B (zh) | Jak2抑制剂在预防和治疗印戒细胞癌中的应用 | |
JP2021063014A (ja) | 白血病治療薬 | |
JP2016521760A (ja) | がんの処置のための、ro5503781、カペシタビン及びオキサリプラチンの組み合わせ | |
CN108743591A (zh) | 用于治疗癌症的药物组合物及其应用 | |
TW202139992A (zh) | 用於癌症治療之醫藥組合 | |
CN117942345A (zh) | 一种arv-825分子配体治疗nut癌方法 | |
CN104825455A (zh) | 依鲁替尼的新用途 | |
CN118252834A (zh) | 维拉佐酮与瑞戈非尼联合用药在治疗结直肠癌中的应用 | |
CN114010642A (zh) | 一种治疗kras突变型肠癌的药物组合物及其联合用药物 | |
NZ789582A (en) | Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |